GoodRx (NASDAQ:GDRX) PT Lowered to $8.00 at Barclays

GoodRx (NASDAQ:GDRX – Get Rating) had its price target dropped by equities researchers at Barclays from $9.00 to $8.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 54.44% from the company’s previous close.

Several other equities research analysts also recently issued reports on the company. The Goldman Sachs Group decreased their price target on GoodRx from $10.00 to $8.00 and set a “neutral” rating for the company in a report on Wednesday, November 9th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of GoodRx from $9.00 to $7.00 in a report on Thursday, November 10th. Citigroup initiated coverage on shares of GoodRx in a report on Thursday, December 1st. They set a “buy” rating and a $7.00 price target on the stock. DA Davidson decreased their price objective on shares of GoodRx to $5.00 in a research note on Tuesday, November 15th. Finally, JPMorgan Chase & Co. upgraded GoodRx from an “underweight” rating to a “neutral” rating and cut their target price for the stock from $10.00 to $8.00 in a research note on Friday, November 4th. Fifteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, GoodRx currently has an average rating of “Hold” and an average target price of $9.45.

GoodRx Trading Down 0.6 %

GDRX opened at $5.18 on Wednesday. GoodRx has a fifty-two week low of $3.82 and a fifty-two week high of $30.89. The firm has a market capitalization of $2.05 billion, a PE ratio of -30.47, a P/E/G ratio of 13.57 and a beta of 0.71. The company has a debt-to-equity ratio of 0.83, a current ratio of 10.34 and a quick ratio of 10.34. The company’s 50-day moving average is $4.94 and its 200 day moving average is $5.55.

Hedge Funds Weigh In On GoodRx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GDRX. Dimensional Fund Advisors LP lifted its stake in shares of GoodRx by 12.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 19,383 shares of the company’s stock valued at $91,000 after buying an additional 2,153 shares in the last quarter. Carmel Capital Partners LLC lifted its position in shares of GoodRx by 6.8% during the third quarter. Carmel Capital Partners LLC now owns 37,248 shares of the company’s stock worth $174,000 after acquiring an additional 2,372 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of GoodRx by 24.0% in the first quarter. Raymond James & Associates now owns 13,806 shares of the company’s stock worth $267,000 after acquiring an additional 2,675 shares during the period. Boothe Investment Group Inc. grew its position in shares of GoodRx by 1.9% in the third quarter. Boothe Investment Group Inc. now owns 212,324 shares of the company’s stock valued at $992,000 after purchasing an additional 3,935 shares in the last quarter. Finally, Advisor Group Holdings Inc. raised its stake in shares of GoodRx by 17.6% during the 1st quarter. Advisor Group Holdings Inc. now owns 28,454 shares of the company’s stock valued at $414,000 after purchasing an additional 4,265 shares during the period. Institutional investors own 35.22% of the company’s stock.

GoodRx Company Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.